Indications And Dose
BEXSERO ® Immunisation against Neisseria meningitidis, primary immunisation ▶BY DEEP INTRAMUSCULAR INJECTION ▶Child 2 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants), for information about the use of paracetamol for prophylaxis of post-immunisation pyrexia, see paracetamol p. 465. ▶Child 4 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants), for information about the use of paracetamol for prophylaxis of post-immunisation pyrexia, see paracetamol p. 465. Immunisation against Neisseria meningitidis, primary immunisation booster dose ▶BY DEEP INTRAMUSCULAR INJECTION ▶Child 12–23 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants) Immunisation against Neisseria meningitidis, primary immunisation (in unimmunised patients) ▶BY DEEP INTRAMUSCULAR INJECTION ▶Child 6–11 months: 0.5 mL for 2 doses, separated by an interval of at least 2 months; booster dose of 0.5 mL given between 1–2 years of age and at least 2 months after completion of primary immunisation, injected preferably into deltoid region (or anterolateral thigh in infants) ▶Child 12–23 months: 0.5 mL for 2 doses, separated by an interval of at least 2 months; booster dose of 0.5 mL given 12–24 months after completion of primary immunisation, injected preferably into deltoid region (or anterolateral thigh in infants) ▶Child 2–10 years: 0.5 mL for 2 doses, separated by an interval of at least 2 months. Injected preferably into deltoid region (or anterolateral thigh in infants) ▶Child 11–17 years: 0.5 mL for 2 doses, separated by an interval of at least 1 month. Injected preferably into deltoid region ▶Adult: 0.5 mL for 2 doses, separated by an interval of at least 1 month. Injected preferably into deltoid region TRUMENBA ® Immunisation against Neisseria meningitidis, primary immunisation ▶BY INTRAMUSCULAR INJECTION ▶Child 10–17 years: 0.5 mL for 2 doses, separated by an interval of 6 months, alternatively 0.5 mL for 2 doses, separated by an interval of at least 1 month, followed by 0.5 mL as a third dose, given at least 4 months after the second dose, injected preferably into deltoid region, a booster dose should be considered for individuals at continued risk—consult product literature ▶Adult: 0.5 mL for 2 doses, separated by an interval of 6 months, alternatively 0.5 mL for 2 doses, separated by an interval of at least 1 month, followed by 0.5 mL as a third dose, given at least 4 months after the second dose, injected preferably into deltoid region, a booster dose should be considered for individuals at continued risk—consult product literature
PDF page 1406